EM-Lux™

The EM-Lux™ platform utilizes advanced optical technologies and automated analysis to investigate novel metabolic biomarkers through a non-invasive approach to embryo and oocyte assessment."

EM-Lux™ Intelligence

  • Absolute Embryo Integrity: The EM-Lux™ system maintains absolute embryo integrity by employing a 100% non-invasive approach for all assessments across the IVF cycle.

  • Multi-Modal Precision: The platform utilizes the proprietary EMMI software for intelligent embryo/egg assessment and ranking , processing complex data to dramatically increase IVF success rates.

  • Real-Science Biomarkers: EM-Lux™ employs real science and microscopy methods to analyze novel metabolic and stress biomarkers non-invasively, providing a superior approach to identify the most viable embryos and eggs.

  • Objective Embryo Assessment: EM-Lux™ is being developed to provide automated, non-invasive viability scoring intended to support embryo selection research throughout the IVF cycle.

  • The EMM (Embryo Morpho-Metabolic Index) Algorithm is the proprietary intelligent software that processes complex metabolic and morphological data to deliver an objective, traceable embryo ranking, maximizing the chance of a successful live birth on the first transfer.

  • EM-Lux™ utilizes established biomedical techniques to deliver non-invasive diagnostics. This "real science" method analyzes the fluorescence response times of fundamental cellular co-enzymes in living embryos and oocytes, which serves as a novel metabolic and stress biomarker. Our proprietary EMMI-AI platform then uses this rich metabolic and morphological data to intelligently assess and rank viability, without the need for biopsy.

  • The primary advantage is that Em-Lux™ is 100% non-invasive for all assessments across the entire IVF cycle. Current standard genetic testing (PGT-a) requires a biopsy, which is an invasive procedure that carries risks of false positives, sampling errors, and potential embryo damage. By using a non-invasive and AI-based technology, EM-Lux™ ensures absolute safety and preserves embryo integrity, offering a faster path to parenthood with fewer risks.

  • Traditional methods rely on either a embryologist's subjective visual grading or an expensive, invasive biopsy. The EM-Lux™ system, powered by the EMMI-AI Platform, introduces objectivity and precision by taking in complex metabolic and morphological data to generate a traceable, data-backed viability score. The AI’s ability to analyze these novel, non-invasive metabolic biomarkers allows it to objectively differentiate between viable (euploid) and non-viable (aneuploid) embryos, effectively reducing the failure rate and accelerating the path to a successful live birth.